source
- First Tracks reports positive early-stage results for celiac drug ANB033First Tracks Biotherapeutics announced that its experimental celiac disease drug ANB033 showed statistically significant improvement in a six‑week early‑stage trial compared with placebo. The trial…
- Bausch + Lomb appoints board chair Thomas Appio as interim CEO after Brent Saunders departsBausch + Lomb announced that board chair Thomas Appio will serve as interim chief executive, taking over immediately from Brent Saunders, who is leaving the role. Appio, who has held several leade…